HighTower Advisors
AIMT

HighTower Advisors’s Aimmune Therapeutics AIMT Stock Holding History

HighTower Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,000
Closed -$8K – 2598
2019
Q4 		$8K Buy
+18,000
New +$503K ﹤0.01% 2210

HighTower Advisors's AIMT Position: Q4 2020 in Review

HighTower Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 11,461 shares — an estimated $395K sold.

HighTower Advisors first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $395K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • HighTower Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • HighTower Advisors sold 11,461 Aimmune Therapeutics shares in Q4 2020, an estimated $395K.
  • HighTower Advisors first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
  • HighTower Advisors's Aimmune Therapeutics position peaked at $395K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.